NasdaqGM:AXSMPharmaceuticals
Assessing Axsome Therapeutics (AXSM) Valuation After Earnings Momentum And New Phase 3 Trial Launch
Axsome Therapeutics (AXSM) has drawn fresh attention after reporting fourth quarter and full year 2025 results, and has also kicked off the CLARITY Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness.
See our latest analysis for Axsome Therapeutics.
The recent CLARITY Phase 3 trial launch and stronger 2025 results come after a period of volatility, with a 1 month share price return of a 10.96% decline and a 90 day share price return of 10.99%. Over...